{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 37,
  "pageCount": 44,
  "prevPage": 36,
  "nextPage": 38,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a timeline-based process diagram to show dose escalation and RP2D selection.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/37",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-37",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.22,
        "x": 0.71,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Phase 2 Expansion Cohorts",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "968ed3c5-2b3c-4dd8-908b-0b57f8160b5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Dose escalation timeline for BA3071",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9067e1fb-c287-4d89-b31e-9dc460a1f3e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "legend",
      "text": "BA3071 monotherapy; BA3071 in combination with nivolumab",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4d97be8-9e4b-4b26-9fae-e521abb3fa84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.18,
        "y": 0.78
      },
      "kind": "list",
      "text": "Determine Phase 2 dose and MTD; Characterize safety and clinical activity; Characterize PK, ADA and biomarkers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "101e75c3-871c-435d-820b-91d790dbdb5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 1/2 trial design for CAB-CTLA-4 Naked Antibody (BA3071)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccdbe901-93cf-438c-9595-e9d1d68c35db",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "758ff659-e575-48c9-9ff9-339149ac2116",
      "evidence": "The timeline structure represents a clinical trial progression.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}